Novozymes A/S (OTCMKTS:NVZMY - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $72.77 and last traded at $71.74, with a volume of 82091 shares trading hands. The stock had previously closed at $70.69.
Novozymes A/S Trading Down 0.7%
The company has a 50-day moving average of $64.84 and a 200-day moving average of $60.13. The company has a market capitalization of $33.56 billion, a price-to-earnings ratio of 45.36, a price-to-earnings-growth ratio of 3.87 and a beta of 0.92.
Novozymes A/S Increases Dividend
The firm also recently announced a dividend, which was paid on Wednesday, April 23rd. Investors of record on Monday, April 7th were given a dividend of $0.3758 per share. This is a positive change from Novozymes A/S's previous dividend of $0.17. The ex-dividend date was Monday, April 7th. Novozymes A/S's dividend payout ratio is currently 47.47%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Featured Articles
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
